K2 Principal Fund, L.P. Alnylam Pharmaceuticals, Inc. Put Options Transaction History
K2 Principal Fund, L.P.
- $307 Million
- Q4 2024
Put Options
2 transactions
Others Institutions Holding ALNY
# of Institutions
676Shares Held
108MCall Options Held
839KPut Options Held
771K-
Capital World Investors Los Angeles, CA16.6MShares$3.98 Billion0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$3.06 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.29 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.97MShares$1.67 Billion0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.38MShares$1.05 Billion0.64% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $29.5B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...